Group 1 - The core point of the announcement is that Zhejiang Yunzhongma Co., Ltd. has approved a capital increase of 300 million RMB to its wholly-owned subsidiary, Zhejiang Yunzhongma Intelligent Manufacturing Co., Ltd. to enhance its core competitiveness and promote the overall business development of the company [3][10][15] Group 2 - The board meeting was held on January 12, 2026, with all 12 directors present, and the meeting followed the legal and regulatory requirements [2][4] - The resolution for the capital increase was passed unanimously with 12 votes in favor, 0 against, and 0 abstentions [4][11] - The company will use self-owned or self-raised funds for the capital increase, and it does not require shareholder approval according to relevant regulations [9][12] Group 3 - The investment is aimed at meeting the operational development needs of the subsidiary and is aligned with the company's overall strategy [15] - The capital increase will not change the scope of the company's consolidated financial statements and will not have a significant impact on the company's financial status or operating results [15]

Focus 1: Rongchang Biologics - Rongchang Biologics signed an exclusive licensing agreement with AbbVie for RC148, potentially receiving up to $4.95 billion in milestone payments [2] - The agreement includes an initial payment of $650 million and tiered royalties based on net sales outside Greater China [2] - This licensing deal is expected to accelerate the global development and commercialization of RC148, enhancing the company's brand value and international influence [2] Focus 2: Jianghuai Microelectronics and Huashi Technology - Jianghuai Microelectronics announced a major matter that may lead to a change in control, resulting in a stock suspension starting January 13, 2026, for up to two trading days [3] - Huashi Technology's major matter also involves potential control changes, with stock suspension effective January 13, 2026, for a similar duration [3] Focus 3: Zhi Te New Materials and *ST Chengchang - Zhi Te New Materials' stock was suspended for review after a 198.57% increase over six consecutive trading days [4] - *ST Chengchang's stock was also suspended due to significant trading anomalies, with four instances of abnormal trading within ten days [4] Earnings Highlights - WuXi AppTec expects a revenue of approximately ¥45.46 billion for 2025, a year-on-year increase of about 15.84%, with a projected net profit of approximately ¥19.15 billion, up 102.65% [6] - Chao Hong Ji anticipates a net profit of ¥436 million to ¥533 million for 2025, representing a growth of 125% to 175% [7] - Asia-Pacific Co. forecasts a net profit of ¥468 million to ¥575 million for 2025, reflecting a growth of 120% to 170% [7] - New Farm Co. expects a net profit of ¥87 million to ¥105 million for 2025, a growth of 50.71% to 81.89% [7] - Cangge Mining anticipates a net profit of ¥3.7 billion to ¥3.95 billion for 2025, a growth of 43.41% to 53.1% [7] - Lianhua Holdings expects a net profit of ¥290 million to ¥330 million for 2025, a growth of 43.15% to 62.90% [8] - Bojun Technology forecasts a net profit of ¥828 million to ¥1.012 billion for 2025, a growth of 35% to 65% [8] - Sanxiang New Materials expects a net profit of approximately ¥100 million to ¥130 million for 2025, a growth of 31.99% to 71.58% [8] Important Matters - Blue Arrow Electronics signed a share acquisition intention agreement to acquire at least 51% of Chengdu Xinyi Technology, with a valuation of up to ¥675 million [12] - The acquisition aims to integrate semiconductor packaging and testing with chip design, enhancing industry synergy [12] - Shanghai Airport received notification of a significant share increase by Taibao Asset, raising its stake to 5% [24] - Kaipu Biotech's actual controller increased shareholding through a block trade, with plans for further purchases [24]

证券日报网讯 1月12日，云中马发布公告称，公司第四届董事会第二次会议审议通过《关于对全资子公 司浙江云中马智造有限公司增资的议案》。 （文章来源：证券日报） ...

云中马（603130）(603130.SH)发布公告，为满足云中马智造经营发展需求，提升其核心竞争力，进而 推动公司整体业务的持续发展，公司拟以自有或自筹资金向全资子公司云中马智造增资人民币3亿元。 ...

智通财经APP讯，云中马(603130.SH)发布公告，为满足云中马智造经营发展需求，提升其核心竞争 力，进而推动公司整体业务的持续发展，公司拟以自有或自筹资金向全资子公司云中马智造增资人民币 3亿元。 ...

格隆汇1月12日丨云中马(603130.SH)公布，为满足云中马智造经营发展需求，提升其核心竞争力，进而 推动公司整体业务的持续发展，公司拟以自有或自筹资金向全资子公司云中马智造增资人民币3亿元。 ...

每经AI快讯，云中马1月12日晚间发布公告称，为满足云中马智造经营发展需求，提升其核心竞争力， 进而推动公司整体业务的持续发展，公司拟以自有或自筹资金向全资子公司云中马智造增资人民币3亿 元。 每经头条（nbdtoutiao）——年产量是传统大田120倍以上，1个人管理1栋楼！实探中国"植物工厂"：水 稻生产期从120天减到60天，没有虫害不用打农药 （记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 ...

证券代码：603130 证券简称：云中马 公告编号：2026-003 浙江云中马股份有限公司 关于对全资子公司浙江云中马智造有限公司 增资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 为满足云中马智造经营发展需求，提升其核心竞争力，进而推动公司整体业 务的持续发展，公司拟以自有或自筹资金向全资子公司云中马智造增资人民币 3 亿元。 | 2.本次交易的交易要素 | | --- | 交易实施尚需履行的审批及其他相关程序 浙江云中马股份有限公司（以下简称"公司"）于 2026 年 1 月 12 日召开第 四届董事会第二次会议审议通过本次增资事项。 根据《上海证券交易所股票上市规则》和《公司章程》的相关规定，本次对 外投资无需提交股东会审议。 其它需要提醒投资者重点关注的风险事项 本次增资对象为公司的全资子公司，整体风险可控，但仍受宏观经济、行业 环境、市场竞争、经营管理等因素的影响，经营状况和收益存在不确定性的风险。 公司将加强对全资子公司云中马智造的运营管控，确保其合规、稳健、高效经营， 提高资金使用效率 ...

证券代码：603130 证券简称：云中马 公告编号：2026-002 （一）审议通过《关于对全资子公司浙江云中马智造有限公司增资的议 案》 为满足浙江云中马智造有限公司经营发展需求，提升其核心竞争力，进而 推动公司整体业务的持续发展，公司拟以自有或自筹资金向全资子公司浙江云 中马智造有限公司增资人民币 3 亿元。公司董事会同意授权董事长或其授权人 士，全权办理本次增资的相关事宜。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江云中马股份有限公司（以下简称"公司"）第四届董事会第二次会议 于 2026 年 1 月 12 日在公司会议室以现场结合通讯的方式召开。会议通知和材料 已于2026 年 1月 7 日以邮件等方式通知全体董事，本次会议应出席董事 12 人，实 际出席董事 12 人（其中，田景岩先生、杨志清先生、金垚先生、徐伟建先生共 4 人以通讯方式出席）。会议的召开和表决程序符合有关法律法规、规章和 《公司章程》《董事会议事规则》的规定。 二、董事会会议审议情况 本次会议审议并通过了以下事项： ...

云中马公告称，公司第四届董事会第二次会议审议通过对全资子公司浙江云中马智造有限公司增资的议 案。为满足其经营发展需求，提升核心竞争力，推动公司整体业务持续发展，公司拟以自有或自筹资金 增资3亿元。董事会同意授权董事长或其授权人士办理增资相关事宜。表决结果为12票同意，0票反对， 0票弃权。 ...